Key result
Cyclophilin A activates and attracts leukocytes via CD147, and its inhibition reduces leukocyte chemotaxis, highlighting it as a potential therapeutic target in inflammatory diseases.
This review highlights the role of cyclophilin A in leukocyte chemotaxis and its potential as a therapeutic target for inflammatory diseases.
Cyclophilin A inhibition may reduce inflammation; hypothesis-generating from Level 5 review and requires prospective trials before clinical adoption.
Cyclophilin A (CypA), a well-recognized receptor for anti-inflammatory drug cyclosporine A (CsA) is a ubiquitous and multifunctional protein. Beside the diverse intracellular functions, CypA is secreted against inflammatory stimuli, where it activates and attracts leukocytes via CD147 to the stimulus site. Interestingly, it synergizes with other factors to induce leukocyte migration in different animals. However, the silencing and inhibition of CypA or CD147 inhibits leukocytes chemotaxis and inflammation. This review focuses on the advances made in understanding the mechanism of CypA-dependent leukocytes chemotaxis and hence, recognition of this factor as a possible therapeutic target in inflammatory diseases.
No takes yet. Share an insight, caveat, or question.
Dawar et al. (2017) conducted a review in Inflammatory diseases. Cyclophilin A (CypA) was evaluated on Leukocyte chemotaxis and inflammation. Cyclophilin A activates and attracts leukocytes via CD147, and its inhibition reduces leukocyte chemotaxis, highlighting it as a potential therapeutic target in inflammatory diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: